Evidence map›Paper›PMID 41813763›Full record

SynthesisScientific reports2026

Efficacy and safety signals from early-phase studies of KRAS inhibition in pancreatic cancer.

Kathlen Oliveira Martins Tiede, Maria Fernanda Teixeira, Mariana Moura, Ohana Chiaini, Fernando Moura, Mohamad Bassam Sonbol, Mitesh Borad, Tanios Bekaii-Saab, Pedro Luiz Serrano Uson Junior

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kathlen Oliveira Martins Tiede *Faculdade de Minas (FAMINAS), Belo Horizonte, Brazil.
Maria Fernanda Teixeira *Center for Personalized Medicine, Hospital Israelita Albert Einstein, Av Albert Einstein 627, São Paulo, Brazil.
Mariana MouraCenter for Personalized Medicine, Hospital Israelita Albert Einstein, Av Albert Einstein 627, São Paulo, Brazil.
Ohana ChiainiFaculdade de Minas (FAMINAS), Belo Horizonte, Brazil.
Fernando MouraCenter for Personalized Medicine, Hospital Israelita Albert Einstein, Av Albert Einstein 627, São Paulo, Brazil.
Mohamad Bassam SonbolMayo Clinic Cancer Center, Phoenix, AZ, USA.
Mitesh BoradMayo Clinic Cancer Center, Phoenix, AZ, USA.
Tanios Bekaii-SaabMayo Clinic Cancer Center, Phoenix, AZ, USA.
Pedro Luiz Serrano Uson JuniorCenter for Personalized Medicine, Hospital Israelita Albert Einstein, Av Albert Einstein 627, São Paulo, Brazil. pedro.serrano@einstein.br.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers, driven by KRAS mutations long deemed "undruggable". We conducted a meta-analysis of seven early phase cohorts (n = 695) that evaluated KRAS-targeted therapies in patients with PDAC. The pooled objective response rate was 29% (95% CI 24-35%), indicating promising activity in refractory PDAC, with consistent estimates across studies (I

Indexed as

Antineoplastic AgentsCarcinoma, Pancreatic DuctalPancreatic NeoplasmsProto-Oncogene Proteins p21(ras)HumansMolecular Targeted TherapyMutationTreatment OutcomeAntineoplastic AgentsKRAS protein, humanProto-Oncogene Proteins p21(ras)

Identifiers

PMID41813763
PMCPMC13103443

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.